Successful chemo-endocrine therapy for multiple bone metastases and myelophthisis caused by occult breast carcinoma

被引：1

作者：

Kanno M. ^{[1
]}

Nakamura S. ^{[2
]}

Uotani C. ^{[1
]}

Yamanaka S. ^{[1
]}

Terasaki Y. ^{[2
]}

Taniya T. ^{[3
]}

Yonezawa T. ^{[4
]}

Yonezawa K. ^{[4
]}

Watanabe K. ^{[5
]}

机构：

[1] Department of Internal Medicine, NTT West Corporation Kanazawa Hospital, 2-16-76 Owari-cho

[2] Third Department of Internal Medicine, Kanazawa University School of Medicine, Kanazawa

[3] Futaba Breast Clinic, Kanazawa

[4] Yonezawa Hospital of Orthopedics, Kanazawa

[5] Department of Pathology, National Kanazawa Hospital, Kanazawa

来源：

International Journal of Clinical Oncology | 2000年 / 5卷 / 6期

关键词：

Chemotherapy; Complete response; Endocrine therapy; Metastatic breast carcinoma; Occult breast carcinoma;

D O I：

10.1007/PL00012070

中图分类号：

学科分类号：

摘要：

We report a 55-year-old postmenopausal woman with occult breast carcinoma with multiple bone metastases and myelophthisis in whom complete response (CR) was achieved with chemo-endocrine therapy. At the time of admission, she had anemia and left axillary lymph node enlargement, with extremely high levels of serum tumor markers and no breast mass on physical examination or on a mammogram. Roentgenograms and bone scintigrams showed multiple bone, lung, and pleural metastases. Bone marrow biopsy and aspiration cytology from the left axillary lymph node revealed an invasion of adenocarcinoma cells. On immunohistochemical staining, the cancer cells were positive for estrogen receptor (ER), progesterone receptor (PgR), and gross cystic disease fluid protein-15 (GCDFP-15). CR was induced with a combination chemotherapy of doxorubicin, cyclophosphamide, and 5-fluorouracil (CAF), and has been maintained with sequential docetaxel administration with endocrine therapy. Her performance status (Eastern Cooperative Oncology Group) improved from 4 to 0. This patient represents a very specific and rare case in whom a primary tumor could not be detected despite severe advanced breast carcinoma, and in whom CR was achieved by chemo-endocrine therapy.

引用

页码：399 / 404

页数：5

共 17 条

[1] Greenberg P.A., Hortobagyi G.N., Smith T.L., Et al., Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer, J Clin Oncol, 14, pp. 2197-2205, (1996)
[2] Rahman Z.U., Frye D.K., Smith T.L., Et al., Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy, Cancer, 85, pp. 104-111, (1999)
[3] Holmes F.A., Walters R.S., Theriault R.L., Et al., Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer, J Natl Cancer Inst, 83, pp. 1797-1805, (1991)
[4] Reichman B.S., Seidman A.D., Crown J.P., Et al., Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer, J Clin Oncol, 11, pp. 1943-1951, (1993)
[5] Buzdar A.U., Holmes F.A., Hortobagyi G.N., Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience, Semin Oncol, 22, SUPPL. 6, pp. 101-104, (1995)
[6] Chevallier B., Fumoleau P., Kerbrat P., Et al., Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer, J Clin Oncol, 13, pp. 314-322, (1995)
[7] Gianni L., Munzone E., Capri G., Et al., Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study, J Clin Oncol, 13, pp. 2688-2699, (1995)
[8] Dieras V., Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer, Semin Oncol, 25, SUPPL. 12, pp. 18-22, (1998)
[9] Nabholtz J.M., Falkson G., Campos D., Et al., A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC, Proc Am Soc Clin Oncol, 18, (1999)
[10] Akasofu M., Kawahara E., Kurumaya H., Et al., Immunohistochemical detection of breast specific antigens and cytokeratins in metastatic breast carcinoma in the liver, Acta Pathol Jpn, 43, pp. 736-744, (1993)

← 1 2 →